JACC: Case Reports (Mar 2024)

Dobutamine-Induced Myoclonus in a Patient With Advanced Heart Failure and Chronic Kidney Disease

  • Alexander Y. Lee, MD,
  • Shiva Barforoshi, MD,
  • Alvin Singh, MD,
  • Ritesh Shrestha, MD,
  • James Ha, MD,
  • Michelle Kittleson, MD, PhD

Journal volume & issue
Vol. 29, no. 6
p. 102255

Abstract

Read online

Dobutamine is a positive inotropic agent often used in treatment of cardiogenic shock. Although there are well-documented adverse effects, dobutamine-induced myoclonus is a rarely reported phenomenon. Our case offers a direct and temporally related description of myoclonus, with onset observed within hours of dobutamine initiation and complete resolution within minutes of discontinuation.

Keywords